GLP-1 Receptor Agonists in Diabetic Nephropathy: Clinical Evidence, Molecular Mechanisms, and Future Perspectives
Turkish Journal of Nephrology
Reviews
Vol. 35 No. 3 (2026): Turkish Journal of Nephrology
DOI: 10.5152/turkjnephrol.2026.251208
Article Sidebar
Full Text PDF
Published: Jul 6, 2026
Keywords
Albuminuria, cardiovascular outcomes, chronic kidney disease, diabetic nephropathy, GLP-1 receptor agonists, renoprotection
How to Cite
Mathew, G. G. (2026). GLP-1 Receptor Agonists in Diabetic Nephropathy: Clinical Evidence, Molecular Mechanisms, and Future Perspectives. Turkish Journal of Nephrology, 35(3), 182–193. https://doi.org/10.5152/turkjnephrol.2026.251208
- ACM
- ACS
- APA
- ABNT
- Chicago
- Harvard
- IEEE
- MLA
- Turabian
- Vancouver
- Endnote/Zotero/Mendeley (RIS)
- BibTeX
Main Article Content
Gerry George Mathew
Department of Nephrology, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur, India
https://orcid.org/0000-0003-1967-4470
GLP-1 Receptor Agonists in Diabetic Nephropathy: Clinical Evidence, Molecular Mechanisms, and Future Perspectives
Main Article Content
Gerry George Mathew
Department of Nephrology, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur, India
https://orcid.org/0000-0003-1967-4470
Abstract
Diabetic nephropathy (DN) remains the predominant etiology of chronic kidney disease (CKD) worldwide, significantly resulting in mortality and morbidity among individuals with diabetes mellitus. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have surfaced as transformative treatment options, offering multifaceted benefits that extend beyond glycemic control. This article explores the comprehensive role of GLP-1RAs in renoprotection and their impact on the progression of DN. Glucagon-like peptide-1 receptor agonists exhibit significant renoprotective effects through multiple mechanisms, including glycemic optimization (HbA1c reduction of 0.73%-3.01%), substantial weight reduction (14%-16% in leading clinical trials), blood pressure reduction (2-6 mmHg systolic reduction), anti-inflammatory effects, and direct albuminuria reduction (11.74%-33%). Major clinical trials, including Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN-6), Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER), Evaluate Renal Function with Semaglutide Once Weekly (FLOW), Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND), consistently demonstrate cardiovascular benefits and slowed CKD progression. Glucagon-like peptide- 1 receptor agonists signify a vital shift in the management of diabetic kidney disease, offering comprehensive metabolic benefits with established renoprotective and cardiovascular advantages.
Cite this article as: Mathew GG. GLP-1 receptor agonists in diabetic nephropathy: clinical evidence, molecular mechanisms, and future perspectives. Turk J Nephrol. 2026;35(3):182-193.
We recommend
- Scorpion Venom and Its Different Peptides Aid in Treatment Focusing on Cancer Disease with the Mechanism of Action Radwa Abdallnasser Amen, et al., Trends in Pharmacy, 2024
- Etrasimod in Treatment of Ulcerative Colitis: A Comprehensive Review Osman Çağın Buldukoğlu, et al., Turkish Journal of Gastroenterology, 2025
- Enteral Nutrition and Pharmacy Practice: Evidence-Based Contributions and the Turkish Experience Betül Özgan, Trends in Pharmacy, 2025
- The Role of Pancreatic Enzyme Insufficiency in the Etiology of Functional Dyspepsia Resistant to Standard Treatment Fatih Kemik, et al., Turkish Journal of Gastroenterology, 2025
- Preparing a Composite Nanofiber Film Using Carbon Nanotubes and Polycaprolactone by Electrospinning Method Gamze Çamlık, et al., Trends in Pharmacy, 2025
- Integrating transcriptomics, metabolomics, and network pharmacology to investigate multi-target effects of sporoderm-broken spores of Ganoderma lucidum on impro... Lidan Hu, Journal of Pharmaceutical Analysis, 2024
- Molecular mechanisms and novel therapeutic targets of diabetic kidney disease Xu, et al., Chinese Medical Journal-Articles in 2026, 2026
- Role of triggering receptor expressed on myeloid cells-1 in kidney diseases: A biomarker and potential therapeutic target Yuxi Fan, et al., Chinese Medical Journal, 2024
- Baicalein: A potential GLP-1R agonist improves cognitive disorder of diabetes through mitophagy enhancement Na Liu, Journal of Pharmaceutical Analysis, 2024
- GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation Jiani Zhong, Journal of Pharmaceutical Analysis, 2024
Powered by
- Do not sell my personal information
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Abstract
Diabetic nephropathy (DN) remains the predominant etiology of chronic kidney disease (CKD) worldwide, significantly resulting in mortality and morbidity among individuals with diabetes mellitus. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have surfaced as transformative treatment options, offering multifaceted benefits that extend beyond glycemic control. This article explores the comprehensive role of GLP-1RAs in renoprotection and their impact on the progression of DN. Glucagon-like peptide-1 receptor agonists exhibit significant renoprotective effects through multiple mechanisms, including glycemic optimization (HbA1c reduction of 0.73%-3.01%), substantial weight reduction (14%-16% in leading clinical trials), blood pressure reduction (2-6 mmHg systolic reduction), anti-inflammatory effects, and direct albuminuria reduction (11.74%-33%). Major clinical trials, including Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN-6), Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER), Evaluate Renal Function with Semaglutide Once Weekly (FLOW), Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND), consistently demonstrate cardiovascular benefits and slowed CKD progression. Glucagon-like peptide- 1 receptor agonists signify a vital shift in the management of diabetic kidney disease, offering comprehensive metabolic benefits with established renoprotective and cardiovascular advantages.
Cite this article as: Mathew GG. GLP-1 receptor agonists in diabetic nephropathy: clinical evidence, molecular mechanisms, and future perspectives. Turk J Nephrol. 2026;35(3):182-193.
